Skip to main content
    S

    Sutro Biopharma (STRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.32
    -0.50 (-5.09%)

    Market Cap: $163.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sutro Biopharma (STRO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Sutro Biopharma reported revenue of $102.48M for the fiscal year ended Dec 31, 2025, up 65.2% from the year before. That year, net income was -$191.09M with a net margin of -186.5%, operating cash flow was -$177.23M and free cash flow was -$178.93M. The quarter ended Sep 30, 2026 had revenue of $9.10M and net income of -$31.49M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $59.73M, a compound annual rate of 6.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$102.48M+65.2%100.0%-154.5%-186.5%
    Dec 2024$62.04M-59.6%100.0%-384.3%-366.6%
    Dec 2023$153.73M+126.8%100.0%-58.1%-69.5%
    Dec 2022$67.77M+9.5%100.0%-190.3%-175.9%
    Dec 2021$61.88M+44.8%100.0%-159.2%-170.6%
    Dec 2020$42.72M0.0%100.0%-166.3%-75.2%
    Dec 2019$42.74M+11.2%100.0%-129.8%-130.4%
    Dec 2018$38.42M-25.7%100.0%-96.9%-91.9%
    Dec 2017$51.74M-13.4%100.0%-37.2%-38.1%
    Dec 2016$59.73MN/A100.0%2.3%2.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$102.48M$62.04M$153.73M$67.77M$61.88M$42.72M$42.74M$38.42M$51.74M$59.73M
    Gross profit$102.48M$62.04M$153.73M$67.77M$61.88M$42.72M$42.74M$38.42M$51.74M$59.73M
    Research and development$166.42M$252.04M$180.43M$137.17M$104.40M$76.96M$65.61M$54.26M$54.64M$43.55M
    Operating income-$158.37M-$238.45M-$89.28M-$128.94M-$98.52M-$71.06M-$55.47M-$37.22M-$19.27M$1.36M
    Net income-$191.09M-$227.46M-$106.79M-$119.20M-$105.54M-$32.13M-$55.74M-$35.32M-$19.69M$1.70M
    EBITDA-$154.48MN/A-$81.62M-$111.49M-$95.35M-$25.75M-$52.15M-$33.21M-$14.18M$7.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$9.10M$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M
    Gross profit$9.10M$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M
    Operating income-$21.96M-$29.89M-$29.66M-$38.05M-$48.46M-$3.35M-$68.51M-$65.26M-$67.92M-$48.69M-$56.59M$43.15M
    Net income-$31.49M-$38.53M-$38.48M-$46.76M-$56.86M-$11.50M-$75.97M-$72.44M-$48.79M-$48.02M-$58.21M$31.07M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $7.78M by $50.35M. Shareholder equity was negative, at -$132.45M, as total liabilities of $306.28M exceeded total assets of $173.83M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$173.83M$387.21M$470.74M$406.94M$341.41M$394.11M$156.37M$223.14M$40.77M$69.28M
    Current assets$150.93M$343.31M$421.54M$353.15M$218.51M$378.18M$128.57M$209.95M$25.63M$49.69M
    Cash and equivalents$58.13M$190.30M$69.27M$47.25M$30.41M$206.15M$4.96M$125.30M$22.02M$11.59M
    Total liabilities$306.28M$342.61M$321.09M$189.90M$88.84M$62.06M$58.58M$91.60M$47.27M$160.18M
    Short-term debt$7.78M$0$4.06M$12.50M$9.38M$0$1.00M$4.72M$14.56M$3.19M
    Long-term debtN/A$0$0$3.77M$15.74M$24.55M$8.88M$10.00M$1.71M$1.19M
    Shareholder equity-$132.45M$44.60M$149.65M$217.05M$252.56M$332.05M$97.79M$131.54M-$109.00M-$90.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$176.65M$194.46M$241.99M$173.83M$209.66M$262.36M$321.43M$387.21M$451.83M$489.04M$403.40M$470.74M
    Total liabilities$309.18M$297.78M$308.88M$306.28M$296.93M$294.47M$347.24M$342.61M$340.61M$336.87M$305.38M$321.09M
    Cash and equivalents$46.85M$54.34M$73.68M$58.13M$65.93M$64.03M$106.23M$190.30M$174.58M$90.79M$65.22M$69.27M
    Shareholder equity-$132.54M-$103.32M-$66.89M-$132.45M-$87.27M-$32.11M-$25.81M$44.60M$111.22M$152.18M$98.02M$149.65M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$177.23M-$191.54M-$111.62M$3.55M-$81.68M-$67.80M-$65.02M$12.68M-$37.07M-$13.15M
    Capital expenditures$1.70M$3.10M$4.32M$7.86M$15.32M$7.13M$3.48M$1.56M$3.32M$4.39M
    Free cash flow-$178.93M-$194.64M-$115.93M-$4.31M-$97.00M-$74.93M-$68.50M$11.13M-$40.39M-$17.55M
    Dividends paidN/AN/AN/A$463.00KN/A$314.00K$297.00KN/AN/AN/A
    Share repurchases$0$0$0$0$7.00K$0$0N/AN/AN/A
    Investing cash flow$45.01M$218.51M-$3.92M-$35.02M-$97.31M$604.00K-$51.13M-$80.19M$32.60M$9.59M
    Financing cash flow$44.00K$94.05M$137.55M$48.31M$3.26M$269.25M-$4.18M$170.78M$14.64M$177.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$22.45M-$38.29M-$42.26M-$26.43M-$38.19M-$44.72M-$67.88M-$71.74M-$64.52M$9.46M-$64.74M$14.07M
    Capital expenditures$132.00KN/A$11.00K$184.00K$251.00K$86.00K$1.17M$1.07M$828.00K$756.00K$446.00K$1.44M
    Free cash flow-$22.58MN/A-$42.27M-$26.62M-$38.44M-$44.81M-$69.06M-$72.81M-$65.34M$8.70M-$65.19M$12.63M
    Last 12 quarters

    Frequently Asked Questions About STRO

    What is Sutro Biopharma's annual revenue?

    Sutro Biopharma reported revenue of $102.48M for the fiscal year ended Dec 31, 2025.

    How fast is Sutro Biopharma's revenue growing?

    Revenue was up 65.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.8%.

    Is Sutro Biopharma profitable?

    No. Sutro Biopharma reported net income of -$191.09M for the fiscal year ended Dec 31, 2025, with a net margin of -186.5%.

    How much free cash flow does STRO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$177.23M minus capital expenditures of $1.70M produced free cash flow of -$178.93M.

    How much debt does Sutro Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $7.78M and cash and equivalents of $58.13M.